PolyActiva is focused on providing unique biodegradable implants with sustained drug delivery to improve patient outcomes and quality of life for patients suffering from ophthalmic diseases such as glaucoma.

PolyActiva

PolyActiva | 1,034 followers on LinkedIn. Enabling Drug Delivery from Medical Devices | PolyActiva is an innovative clinical-stage ophthalmology company with a unique proprietary polymeric prodrug technology that enables site-specific, precise and controlled drug delivery to the eye.

With the PolyActiva technology, exceptional zero-order release profiles are achieved over treatment periods ranging from 6 to 12 months.

Our mission is to become a leader in ophthalmic medicine by providing unique biodegradable implants with sustained drug delivery to improve patient outcomes and quality of life.

CEO at PolyActiva Pty Ltd

Vanessa Waddell

Nonclinical and Formulation Leader at PolyActiva | Pharmacist | Polymeric Drug Delivery | Physical Pharmacy

Igor Chekhtman

Analytical R&D Team Leader with PolyActiva (Biotechnology)

Tiffany Reeves

Head, Product Development and Technical Affairs at PolyActiva

Justine Walter

Thank you Brandon Capital , along with all of our other incredible shareholders, for supporting us through these vital stages of development! Support from local VCs and investors allows Australian-made, innovative products like ours the chance to capture markets globally! Something we’ll be focussing on in our pivotal late-stage clinical trials early 2025 under our IND submission to the FDA #glaucoma #investment #biotechnology #innovation

👁️ PolyActiva is thrilled to report our latest clinical data from our Phase 2a trial testing PA5108, a 6-month sustained-release ocular implant for patients suffering from glaucoma. PA5108 has successfully met the safety and efficacy endpoints in the repeat-dose cohort, demonstrating a statistically significant change from baseline in intraocular pressure (IOP) at weeks 12, 21, 33 and 42 (p<0.0001). Clinically meaningful IOP reductions of 26-35% were observed over 48 weeks. Most importantly to us, the implant was found to be safe and generally well tolerated by trial participants following repeat-dosing over 48 weeks of monitoring! These results demonstrate that PA5108 could be used to treat patients' glaucoma long-term over multiple doses without the compliance and dosing issues that come with drop therapy. PolyActiva is scaling up our manufacturing capabilities to support the commencement of late-stage clinical trials in early 2025, with trials to be conducted under an IND submission to the FDA. Read the full statement here: https://lnkd.in/gvB4QRhW #Glaucoma #DrugDelivery #Biotechnology #Innovation

Vanessa Waddell presents PolyActiva at #AusBioInv highlighting their implantable treatment for glaucoma.

Lis Boyce

Great to catch up with Vanessa Waddell CEO of PolyActiva at the AusBiotech #AusBioInv Exciting new data on the safe and effective glaucoma treatment developed here in Australia. #Ausbiotech24 Chris Nave Chris Smith Bob Soh Brandon Capital

MARILYN JONES

🚨 PolyActiva 's CEO, Vanessa Waddell , and our Head of Product Development & Technical Affairs, Justine Walter , will both be attending AusBiotech 2024 starting tomorrow at Melbourne's Convention & Exhibition Centre. With so many incredible industry leaders and experts attending, we can't wait to see what the next few days has in store for us! If you're in the area and would like to catch up with our team, reach out and say hello 👋 We'd love to fill you in on what we've been up to! #Ausbiotech2024 #Innovation #Biotech #Investment

PolyActiva is excited to announce that our CEO, Vanessa Waddell , will be presenting at #AusBioInvest24 on 29 October in the 4:00pm – 4:55pm session. Vanessa will be presenting our latest 48-week clinical data from our Phase 1b/2a clinical trial, which demonstrates both the safety of repeat-dosing with our PA5108 Ocular Implant, and sustained reduction in intraocular pressure in this repeat-dose cohort out to 48 weeks. This data backs our goal of providing patients suffering from glaucoma a long-term sustained-release alternative solution to drop therapy. Thank you AusBiotech for this opportunity, we can’t wait to share these results with you and what we have on the horizon. #AusBio #AusBioInv24 #Glaucoma #Innovation

We're incredibly proud of our CEO Vanessa Waddell 's recent presentation at Eyecelerator @ AAO2024 last week. Vanessa got the chance to present our new 48-week clinical data from our Phase 1b/2a clinical trial, which demonstrates both the safety of our PA5108 after repeat-dosing, as well as a sustained reduction in intraocular pressure out to 48 weeks. These results are the culmination of over a decade of research and work by our incredible team, with help from countless other consultants and clinicians along the way. It's exciting to be another step closer to providing patients suffering from glaucoma a safe and effective sustained-release implant as an alternative to drop therapy! #Glaucoma #Biotech #Innovation #AAO2024

PolyActiva 's Nonclinical & Formulation Leader Dr. Igor Chekhtman , and Commercial Operations & BD Associate Alexander Goulsbra attended the BioConnections 2024 Conference last week. Thank you to Informa Australia for putting together such an insightful conference with incredible keynote speakers and excellent panel discussions! It was also great to catch up with Camille Shanahan from Jumar Bioincubator , where PolyActiva is utilising their state-of-the-art laboratories to continue manufacturing our ocular implants locally, ready for our upcoming clinical trial program. #BioConnexAus #Glaucoma #Innovation #Incubator #Biotech

The PolyActiva Polymer Chemistry Team has had a busy week setting up the cleanrooms at Jumar in Melbourne so we can keep the manufacture of our phase 1 clinical trial material local. With limited options for manufacturing our ocular implants, access to Jumar’s state-of-the-art laboratories provides us with the opportunity to build our ocular implant manufacturing capabilities internally rather than having to go offshore. It’s an exciting time, and we’re also looking forward to joining a community fostering the next generation of Australian biotech

PolyActiva 's Head of Polymers & Medical Devices, Dr. David Valade will be presenting at PharmOut 's Pharma & Device Forum 2024 this Friday 24 May at the Melbourne Exhibition and Convention Centre in Melbourne, Australia. David will be discussing the hurdles PolyActiva has overcome to manufacture our unique sustained-release, biodegradable ocular implants for use in our clinical trial programs. If you're attending this event, you can catch David's presentation in Room 103 from 2:00pm - 2:30pm AEST. Come and say hi! #Glaucoma #Pharmaceutical #Manufacturing #Innovation

Metric
Company Name	PolyActiva
Symbol
MSH ID	COM:POLYACTIVA
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Medical Devices
Country	AU
Stage	Grant
Employee Count
Website	polyactiva.com
LinkedIn	polyactiva
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital	988.31K

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

POLY

COM:POLYACTIVA

PolyActiva

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue